NEW YORK, Oct. 31, 2014 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced ANGLE plc (AIM: AGL; OTCQX: ANPCY), a specialist medical diagnostics company, has qualified to have its American Depositary Receipts (ADRs) trade on OTCQX®, the best marketplace.
ANGLE begins trading today on OTCQX under the symbol "ANPCY," where each ADR represents 10 ordinary shares. U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.
"We are pleased to welcome ANGLE to the OTCQX marketplace," said R. Cromwell Coulson, President and CEO of OTC Markets Group. "ANGLE joins the growing number of global companies that are choosing to trade on OTCQX to provide U.S. investors transparent trading and convenient access to their news and financials so they can more easily analyze, value and trade their securities. We look forward to supporting ANGLE as the company expands its presence in the U.S. market."
ANGLE's Founder and Chief Executive, Andrew Newland, commented, "We believe that the steps that we are taking will substantially strengthen ANGLE's position in the United States, the world's largest market for medical diagnostics. The ADR program on the OTCQX marketplace will meet U.S. investor demand and increase liquidity in ANGLE's shares to the benefit of our shareholders."
Aegis Capital Corp. serves as ANGLE's Principal American Liaison ("PAL") on OTCQX, responsible for providing professional guidance on OTCQX requirements.
ANGLE is a commercially driven specialist medical diagnostic company with pioneering products in cancer diagnostics and fetal health.
ANGLE's lead product is the Parsortix cell separation system, which can capture very rare cells from blood. This includes circulating tumor cells (CTCs) in cancer patient blood even when there is less than one CTC in one billion healthy cells. The resulting liquid biopsy (simple blood test) enables the investigation of mutations in the patient's cancer for personalized cancer care.
ANGLE has launched a product for the research market and has secured CE Mark regulatory approval for the clinical market in Europe. The FDA authorization is in process.
About OTC Markets Group Inc.
OTC Markets Group Inc. (OTCQX: OTCM) operates Open, Transparent and Connected financial marketplaces for 10,000 U.S. and global securities. Through our OTC Link® ATS, we directly link a diverse network of broker-dealers that provide liquidity and execution services for a wide spectrum of securities. We organize these securities into marketplaces to better inform investors of opportunities and risks – OTCQX®, The Best Marketplace; OTCQB®, The Venture Marketplace; and OTC Pink®, The Open Marketplace. Our data-driven platform enables investors to easily trade through the broker of their choice at the best possible price and empowers a broad range of companies to improve the quality and availability of information for their investors. To learn more about how we create better informed and more efficient financial marketplaces, visit www.otcmarkets.com.
OTC Link ATS is operated by OTC Link LLC, member FINRA/SIPC and SEC regulated ATS.
SOURCE OTC Markets Group Inc.